Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV

Core Insights - Theratechnologies Inc. is set to present three posters at IDWeek 2024, focusing on innovative therapies for HIV-related health issues [1][3] Group 1: Poster Presentations - One poster will discuss the link between excess visceral abdominal fat (EVAF) and increased cardiovascular risk in individuals with HIV [2] - Another poster will present findings on how tesamorelin, a growth hormone-releasing factor analog, can reduce EVAF and lower cardiovascular disease risk in HIV patients [2] - A third poster will outline the study design and baseline characteristics of the PROMISE-US trial, which examines the outcomes of multidrug-resistant HIV patients treated with ibalizumab [2][4] Group 2: Event Details - IDWeek 2024 will take place from October 16-19 in Los Angeles, California, and is a significant meeting for professionals in infectious diseases [1][4] - The presentations will occur on October 17, 2024, during sessions focused on HIV complications and treatment [4] Group 3: Company Overview - Theratechnologies is a biopharmaceutical company dedicated to developing and commercializing innovative therapies that address unmet medical needs [5]